Patents by Inventor Sodhi P. Chhinder

Sodhi P. Chhinder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS
    Publication number: 20190374562
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: April 17, 2019
    Publication date: December 12, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
    Patent number: 10300083
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 28, 2019
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS
    Publication number: 20170095493
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
    Patent number: 9532999
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: January 3, 2017
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS
    Publication number: 20150250809
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: May 20, 2015
    Publication date: September 10, 2015
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
    Patent number: 9072760
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: July 7, 2015
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam